Hansa Biopharma AB (HNSA.ST) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Sweden · ISIN SE0002148817
Hansa Biopharma AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 171.32 m SEK | 222.27 m SEK |
| Gross profit | 87.76 m SEK | 138.71 m SEK |
| Operating income | -637.88 m SEK | -520.71 m SEK |
| EBIT | -670.13 m SEK | -522.58 m SEK |
| Net income | -807.24 m SEK | -534.11 m SEK |
| Diluted EPS – continuing operations | -12.85 SEK | -6.58 SEK |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
More stocks
- Guangzhou Jinzhong Auto Parts Manufacturing Co. Ltd. (301133.SZ)
- Cuckoo Homesys Co Ltd (284740.KS)
- Lungteh Shipbldg Co Ltd (6753.TW)
- Jinsanjiang (Zhaoqing) Silicon Material Company Limited (301059.SZ)
- Shenzhen Neoway Technology Co Ltd (688159.SS)
- NorthEast Community Bancorp, Inc./MD/ (NECB)
- SNTEnergy Co Ltd (100840.KS)
- Ascencio (D) (ASCE.BR)
- Bemobi Mobile Tech S.A (BMOB3.SA)
- Hey-Song Corp (1234.TW)
- Suzhou Weizhixiang Food Co. Ltd. (605089.SS)
- Ningbo Xianfeng New Material (300163.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.